Abstract
Genetic immunization with lentiviral vectors is under evaluation as a means for induction of sustained immune response. Lentiviral vectors showed reduced antivector immune responses and efficiently transduced post-mitotic cells in vivo, including antigen presenting cells, such as dendritic cells and macrophages, thus providing a significant benefit over other vector-based antigen delivery platforms. Several evidences indicate that a single immunization with lentiviral vectors induces strong and sustained effector and memory T-cell immune responses, as well as antibody production. New generation of lentiviral vectors with improved biosafety profile are also under development. In particular, integration defective lentiviral vectors have been generated and used as an efficient and safe delivery system for both gene therapy and immunization purposes. Taken together, these evidences support the ongoing development of lentiviral vector-based genetic immunization strategies for safe applications in the clinic.
Keywords: Lentiviral vector, integrase, immunization, vaccine
Current HIV Research
Title: Toward Integrase Defective Lentiviral Vectors for Genetic Immunization
Volume: 8 Issue: 4
Author(s): Donatella R.M. Negri, Zuleika Michelini and Andrea Cara
Affiliation:
Keywords: Lentiviral vector, integrase, immunization, vaccine
Abstract: Genetic immunization with lentiviral vectors is under evaluation as a means for induction of sustained immune response. Lentiviral vectors showed reduced antivector immune responses and efficiently transduced post-mitotic cells in vivo, including antigen presenting cells, such as dendritic cells and macrophages, thus providing a significant benefit over other vector-based antigen delivery platforms. Several evidences indicate that a single immunization with lentiviral vectors induces strong and sustained effector and memory T-cell immune responses, as well as antibody production. New generation of lentiviral vectors with improved biosafety profile are also under development. In particular, integration defective lentiviral vectors have been generated and used as an efficient and safe delivery system for both gene therapy and immunization purposes. Taken together, these evidences support the ongoing development of lentiviral vector-based genetic immunization strategies for safe applications in the clinic.
Export Options
About this article
Cite this article as:
R.M. Negri Donatella, Michelini Zuleika and Cara Andrea, Toward Integrase Defective Lentiviral Vectors for Genetic Immunization, Current HIV Research 2010; 8 (4) . https://dx.doi.org/10.2174/157016210791208622
DOI https://dx.doi.org/10.2174/157016210791208622 |
Print ISSN 1570-162X |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4251 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
The Combination of New Immunotherapy and Radiotherapy: A N ew Potential Treatment for Locally Advanced Non-Small Cell Lung Cancer
Current Clinical Pharmacology Treatment of Antipsychotic-Induced Hyperprolactinemia: An Update on the Role of the Dopaminergic Receptors D2 Partial Agonist Aripiprazole
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery (Discontinued) Synthetic Androgens as Designer Supplements
Current Neuropharmacology Benzimidazole Derivatives as Potential Anticancer Agents
Mini-Reviews in Medicinal Chemistry Targeting Cancer Cells by an Oxidant-Based Therapy
Current Molecular Pharmacology Modulation of the Immune Response by Targeting Endothelial Cells
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Epigenetic Regulation and Therapeutic Approaches in Cancer
Current Topics in Medicinal Chemistry Anionic Antimicrobial Peptides from Eukaryotic Organisms
Current Protein & Peptide Science Detecting Growing Mammary Tumors with Monoclonal Antibodies Against Vascular Endothelial Growth Factor Receptor – 3
Current Radiopharmaceuticals Prophylactic Vaccine Approach for Colon and Pancreatic Cancers: Present and Future
Current Medicinal Chemistry Microdialysis: A Technique for Pharmacokinetic-Pharmacodynamic Studies of Oncological Drugs
Current Pharmaceutical Biotechnology Plant Ribonucleases and Nucleases as Antiproliferative Agens Targeting Human Tumors Growing in Mice
Recent Patents on DNA & Gene Sequences Natural Endoperoxides as Drug Lead Compounds
Current Medicinal Chemistry The Interaction of Histone Deacetylase Inhibitors and DNA Methyltransferase Inhibitors in the Treatment of Human Cancer Cells
Current Medicinal Chemistry - Anti-Cancer Agents Discovering Tumor Suppressor Genes Through Genome-Wide Copy Number Analysis
Current Genomics Thromboembolic Complications in Malignant Haematological Disorders
Current Vascular Pharmacology Disorders of Innate Immunity in Human ageing and effects of Nutraceutical Administration
Endocrine, Metabolic & Immune Disorders - Drug Targets Use of Insulin and Insulin Analogs and Risk of Cancer — Systematic Review and Meta-Analysis of Observational Studies
Current Drug Safety Molecular Mechanisms of Pancreatic Cancer Dissemination: The Role of the Chemokine System
Current Pharmaceutical Design Delivery of Peptidic Gonadotropin Releasing Hormone Antagonists
Current Drug Delivery